BR112015015864A8 - pharmaceutical composition and use of a pharmaceutical composition - Google Patents

pharmaceutical composition and use of a pharmaceutical composition

Info

Publication number
BR112015015864A8
BR112015015864A8 BR112015015864A BR112015015864A BR112015015864A8 BR 112015015864 A8 BR112015015864 A8 BR 112015015864A8 BR 112015015864 A BR112015015864 A BR 112015015864A BR 112015015864 A BR112015015864 A BR 112015015864A BR 112015015864 A8 BR112015015864 A8 BR 112015015864A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
preparing
individual
methods
Prior art date
Application number
BR112015015864A
Other languages
Portuguese (pt)
Other versions
BR112015015864A2 (en
BR112015015864B1 (en
Inventor
Brew John
Mark Bannister Robin
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Publication of BR112015015864A2 publication Critical patent/BR112015015864A2/en
Publication of BR112015015864A8 publication Critical patent/BR112015015864A8/en
Publication of BR112015015864B1 publication Critical patent/BR112015015864B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica, mã‰todo de preparaã‡ãƒo de uma composiã‡ãƒo farmacãšutica, mã‰todo de tratamento de um indivãduo com uma condiã‡ãƒo de dor severa, e, uso de uma composiã‡ãƒo farmacãšutica ” a presente especificaã§ã£o divulga composiã§ãµes farmacãªuticas, mã©todos de preparaã§ã£o de tais composiã§ãµes farmacãªuticas e mã©todos e usos de tratamento de uma inflamaã§ã£o crã´nica e/ou uma doenã§a inflamatã³ria em um indivã­duo usando tais composiã§ãµes farmacãªuticas.1 / 1 abstract pharmaceutical composition, method of preparing a pharmaceutical composition, method of treating an individual with a condition severe pain, and use of a pharmaceutical composition The present specification discloses pharmaceutical compositions, methods of preparing such compositions pharmaceuticals and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

BR112015015864-1A 2013-01-14 2014-01-14 USE OF A PHARMACEUTICAL COMPOSITION IN THE TREATMENT OF A SEVERE PAIN CONDITION BR112015015864B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752356P 2013-01-14 2013-01-14
US61/752,356 2013-01-14
PCT/EP2014/050628 WO2014108569A1 (en) 2013-01-14 2014-01-14 Compositions and methods for treating severe pain

Publications (3)

Publication Number Publication Date
BR112015015864A2 BR112015015864A2 (en) 2017-07-11
BR112015015864A8 true BR112015015864A8 (en) 2018-01-16
BR112015015864B1 BR112015015864B1 (en) 2022-08-23

Family

ID=50064547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015864-1A BR112015015864B1 (en) 2013-01-14 2014-01-14 USE OF A PHARMACEUTICAL COMPOSITION IN THE TREATMENT OF A SEVERE PAIN CONDITION

Country Status (14)

Country Link
EP (1) EP2943183A1 (en)
JP (1) JP6474732B2 (en)
KR (1) KR20150129665A (en)
CN (1) CN104968330A (en)
AU (1) AU2014204739B2 (en)
BR (1) BR112015015864B1 (en)
CA (1) CA2897874A1 (en)
HK (1) HK1217650A1 (en)
IL (1) IL239921A0 (en)
MX (1) MX2015009045A (en)
RU (1) RU2677346C2 (en)
SG (1) SG11201505245XA (en)
WO (1) WO2014108569A1 (en)
ZA (1) ZA201505005B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11896037B2 (en) * 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
JP7027786B2 (en) * 2017-10-12 2022-03-02 ライオン株式会社 Oral treatment for myofascial pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
SI0989851T1 (en) * 1997-07-29 2003-04-30 Pharmacia & Upjohn Company Self-emulsifying formulation for acidic lipophilic compounds
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000067728A2 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
TR200200562T2 (en) * 1999-06-14 2002-05-21 Cosmo S.P.A Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP3763567B2 (en) * 2001-01-19 2006-04-05 株式会社資生堂 Cosmetics
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
AU2006240551A1 (en) * 2005-04-28 2006-11-02 Dsm Ip Assets B.V. Pharmaceutical dosage forms comprising a lipid phase
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2009153496A2 (en) 2008-05-26 2009-12-23 Genfit Ppar agonist compounds, preparation and uses
CN102048680B (en) * 2009-11-11 2013-05-01 河北奥星集团药业有限公司 Enteric sustained-release preparation containing zaltoprofen and preparation method thereof
BR112013019734A2 (en) * 2011-02-04 2016-10-25 Biocopea Ltd compositions and methods for treating chronic inflammation and inflammatory diseases
CN102579350B (en) * 2012-03-02 2013-04-24 海南灵康制药有限公司 Pidotimod liposome solid preparation

Also Published As

Publication number Publication date
JP6474732B2 (en) 2019-02-27
RU2677346C2 (en) 2019-01-16
BR112015015864A2 (en) 2017-07-11
HK1217650A1 (en) 2017-01-20
KR20150129665A (en) 2015-11-20
AU2014204739A1 (en) 2015-07-16
RU2015134136A (en) 2017-02-20
ZA201505005B (en) 2016-10-26
BR112015015864B1 (en) 2022-08-23
SG11201505245XA (en) 2015-08-28
MX2015009045A (en) 2015-12-17
EP2943183A1 (en) 2015-11-18
CN104968330A (en) 2015-10-07
CA2897874A1 (en) 2014-07-17
IL239921A0 (en) 2015-08-31
AU2014204739B2 (en) 2016-08-11
JP2016504401A (en) 2016-02-12
WO2014108569A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
BR112015015864A8 (en) pharmaceutical composition and use of a pharmaceutical composition
BR112015015898A8 (en) solid solution pharmaceutical composition and use of a pharmaceutical composition
BR112015015870A8 (en) pharmaceutical composition and use of a pharmaceutical composition
WO2015077503A8 (en) Autotaxin inhibitor compounds
CL2013001654A1 (en) Compounds derived from 6-amino-2-phenylamino-1h-benzimidazol-5-carboxamide; pharmaceutical composition; and its use in the treatment and / or prevention of inflammatory diseases and / or associated conditions, in particular pain.
CR20150476A (en) OXOPYRIDINE SUBSTITUTED DERIVATIVES AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
MX2013008851A (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
GT201600002A (en) BENCIL-1H-PIRAZOLO [3,4-B] PIRIDINES AND ITS USE
BR112016011789A2 (en) PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND THEIR USE
MX2019005151A (en) Pertuzumab variants and evaluation thereof.
BR112017005209A2 (en) rorc2 methyl and trifluoromethyl substituted pyrrolopyridine modulating compounds and their use
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
UY33219A (en) CYCLIC CETOENOLS FOR THERAPIES
MX2018007871A (en) Personal care composition comprising taurine, arginine, glycine.
BR112015022196A2 (en) prolonged release compositions comprising hydrocodone and acetaminophen for rapid onset and prolonged analgesia which may be administered independently of food
BR112017016388A2 (en) cenicriviroc for the treatment of fibrosis
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EA201690574A1 (en) APPLICATION OF PIDOTIMODE IN THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
BR112016006244A2 (en) methods of using secretory iga
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
WO2015004634A3 (en) Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2014, OBSERVADAS AS CONDICOES LEGAIS